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Disparities in first-to-second dose measles-
containing vaccination coverage: A comparative 
analysis of the predictive power of three economic 
indices
Justin McDaniel1*, Aaron Diehr2 and Dominique Rose2
Abstract: While overall mortality from measles has decreased, it is still associ-
ated with significant global infant deaths. Studies indicate that a second dose of 
measles-containing vaccine (MCV) is necessary to produce sufficient immunity to 
measles, yet several developing countries are deficient of a two-dose schedule. This 
study examined the efficacy of three economic indices—the Human Development 
Index (HDI), the Inequality-adjusted Human Development Index (IHDI), and the 
Multidimensional Poverty Index (MPI)—in predicting first-to-second MCV dosage 
disparities. Country-level data for MCV coverage were downloaded from the World 
Health Organization (WHO). Briggsian logarithmic regression models of MCV dosage 
disparities were calculated to compare the predictive power of the HDI, IHDI, and 
MPI. The MPI explained the most variance in dosage disparities, F (1, 54) = 41.835, 
p < 0.001, R2 = 0.437, b = 0.938, followed by the IDHI (R2 = 0.361, b = −0.935) and 
HDI (R2 = 0.354, b = −1.023). We suggest the MPI explained the greatest variance 
because it uses multiple indicators to determine poverty across three dimensions 
of human development. The MPI predicted larger disparities in more developing 
countries. Future efforts should be directed toward discovering and reducing barriers 
to second dose MCV administration in these countries.
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PUBLIC INTEREST STATEMENT
While the number of deaths per year from 
Measles has decreased globally, likely as a result 
of the introduction of the measles-containing 
vaccination (MCV), said disease still accounts for 
a significant amount of infant deaths. Immunity 
from measles is dependent upon the uptake of the 
first and second dose of the MCV; however, many 
countries do not have access to the second dose 
of the MCV—leading to incomplete immunity. We 
showed, via predictive modeling, that impoverished 
countries around the world have greater disparities 
in first-to-second dose MCV coverage. That is, 
underserved countries experience barriers in 
access to the second dose of the MCV. Future 
public health efforts should be directed toward 
eliminating the barriers that prohibit impoverished 
countries from gaining access to the second dose 
of the MCV. Greater second dose MCV coverage 
may minimize the burden of the measles disease, 
especially among children.
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1. Introduction
Before extensive vaccination measures were introduced, measles occurred in 95–98% of children by 
the age of 18, was considered an inevitable part of childhood (Perry & Halsey, 2004), and resulted in 
approximately 2.6 million deaths per year (World Health Organization [WHO], 2015a). However, 
measles can affect people of all ages and the complications associated with the infection present a 
rationale for its eradication (WHO, 2009).
Measles, also known as Rubeola, is an acute infection caused by a morbillivirus from the para-
myxovirus group (DiPaola, Michael, & Mandel, 2012). Measles is one of the most highly communica-
ble infectious diseases, which can be transmitted through airborne contact by coughing or sneezing. 
Because the virus can live on a surface or in airspace for up to two hours, transmission requires no 
direct contact with an infected person (Centers for Disease Control, 2014).
Vaccinations have been effective in reducing the incidence of measles, and measles is no longer 
endemic in the United States or in many other developed country throughout the world (Perry et al., 
2015; Salsibury & Ramsay, 2013). One dose of the combined measles, mumps, and rubella (MMR) 
vaccine is estimated to be 95% effective in protecting against measles, and infections are extremely 
unlikely in individuals who have received two doses of the vaccine (Demicheli, Rivetti, Debalini, & Di 
Pietrantonj, 2012).
1.1. Vaccination disparities in developing countries
The WHO recommends children receive their first dose of measles-containing vaccine (MCV-1) at the 
age of nine months or one year and the second dose (MCV-2) between 15 and 18 months. For coun-
tries where measles mortality is high, a two-dose schedule is particularly important, as MCV-2 has 
been shown to reduce the rate of accretion and the possibility of an occurrence (WHO, 2015c). In 
impoverished countries, infectious diseases—such as measles—still account for a significant pro-
portion of deaths. Accordingly, developing countries continue to hold lower levels of immunization, 
especially as regards the second dose of MCV. Meheus and Van Doorslaer (2008) examined the dis-
tribution of measles immunization and the socioeconomic trends for 21 countries and found that, 
among impoverished countries, socioeconomic inequalities in measles immunization rates are high-
er for the underprivileged and individuals living in impoverished areas (Meheus & Van Doorslaer, 
2008).
Various hypotheses have been suggested to explain immunization inequalities among popula-
tions. Research has highlighted socioeconomic status, education (Desai & Alva, 1998), and indirect 
costs, such as transportation (Jordan et al., 2006), as predictors of vaccination inequality. Lower 
vaccination coverage in children has also been linked with parental unemployment, less parental 
education, (Vandermeulen et al., 2008), single parent households, mothers under the age of 20, 
(Pearce et al., 2008), lack of health insurance coverage, lower overall household income (Bates, 
Fitzgerald, Dittus & Wolinsky, 1994), and greater levels of residential mobility (Nagaoka, Fujiwara, & 
Ito, 2012). Overall, a confluence of factors likely influence vaccination uptake, many of which un-
doubtedly are linked with poverty. Research has continually reminded us that individuals negatively 
affected by poverty are generally the most deprived in society, and this lack of resources can—and 
often does—have an adverse affect on an individual’s health (Murtaza, Mustafa, & Awan, 2015).
1.2. Poverty indices
Health can be influenced by many factors, such as education, income, access to healthcare services, 
and employment. The level of development—or conversely, the amount of poverty—in a population 
should hence predict vaccination coverage in a population. The Human Development Index (HDI) is 
a composite statistic of income per capita, education, and life expectancy indicators, which are used 
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to rank countries (United Nations Development Programme [UNDP], 2015). The HDI specifically fo-
cuses on three dimensions of human development: the ability to acquire knowledge (measured by 
average years and expected years of schooling), an individuals’ capability to lead a long and healthy 
life (measured by life expectancy at birth), and an individual’s ability to achieve a decent standard of 
living (measured by the gross national income per capita) (UNDP, 2015). The Inequality Adjusted 
Human Development Index (IHDI) adapts the HDI to the magnitude of inequality. According to Ruiz 
et al. (2015), “The IHDI takes into account how education, health, and income achievements are 
distributed among the population of each country and the difference between the IHDI and HDI in-
forms the loss of human development due to inequality” (p. 2). Lastly, the Multidimensional Poverty 
Index (MPI) measures non-income dimensions of poverty (UNDP, 2015). The MPI evaluates poverty 
at the individual level. The MPI can be used to construct a comprehensive picture of individuals living 
in poverty, allowing for comparisons across regions, countries, and the world. It can also display 
comparisons within countries by urban/rural location, as well as significant household and commu-
nity characteristics.
The three economic indicators previously described (i.e. the HDI, IHDI, and the MPI) are all used to 
determine the level of poverty in a country. The objective of the present study, then, was to examine 
which of these three economic indicators could explain the most variance in first to second dose 
measles vaccination coverage disparities among the most impoverished countries. Like many other 
composite measures and indices, the HDI, IHDI, and MPI have limitations. So as to keep these indices 
interpretable to the public, the factors and dimensions used to calculate the indices have been kept 
to a minimum; therefore, these indices provide only a snapshot of human development and poverty 
in a country, not a comprehensive picture (UNDP, 2015).
2. Methods
2.1. Data collection
Country-level data was downloaded for the present post-positivist (Phillips & Burbules, 2000), eco-
logical (Jacobson, 2012) study from two sources. First, data on measles-containing vaccination 
(MCV) coverage in 2014—both first dose and second dose—were retrieved from the WHO vaccine 
preventable diseases monitoring system 2015 global summary (WHO, 2015b). Second, economic in-
dicators—specifically the HDI, IHDI, and MPI—were downloaded from the UNDP’s, 2015 Human 
Development Report (UNDP, 2015).
The following sample sizes were available for each of the aforementioned variables: first dose MCV 
coverage (MCV-1; n = 181), second dose MCV coverage (MCV-2; n = 134), HDI (n = 188), IHDI (n = 188), 
and MPI (n = 101). Because many countries in the data-set did not have data available across all 
variable categories, the data-set was reduced so as to permit commonality—similar to the methods 
used in Nuhu, McDaniel, and Ruiz’s (2015) paper. After the elimination of countries deficient of data 
in one or more of the variable categories, the final sample size for the present study was 56. In other 
words, secondary data were available for all variables in the study among 56 underserved countries. 
The study population, then, was confined to those countries studied for the creation of the MPI.
2.2. Data analysis
The dependent variable in the present study was thus: first to second dose disparities in MCV (calcu-
lated by subtracting the percentage of the population with the second dose of the MCV from the 
percentage of the population with the first dose of the MCV). ESRI ArcGIS was utilized to represent 
disparities in MCV coverage (Figures 1 and 2). Regarding the maps, graduated symbols were used to 
represent MCV coverage - where countries with darker colors exhibited lower MCV coverage. As such, 
larger numbers indicated greater disparity between first and second dose MCV coverage. The HDI, 
IHDI, and the MPI were used as independent variables in the present study.
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Means and standard deviations were calculated for each variable in the study. In order to deter-
mine which of the three independent variables had the greatest predictive power for first to second 
dose disparities in MCV coverage among underserved countries, Ordinary Least Squares (OLS) re-
gression was used (Hoy, Livernois, McKenna, Rees, & Stengos, 2001). Because the residuals for each 
regression model did not conform to the Gaussian distribution, a Briggsian logarithmic transforma-
tion, with a constant of 30, was applied to the dependent variable (Gonzalez-Velasco, 2010). Slight 
departures from normality were present after the data transformation. Therefore, each regression 
model was bootstrapped with 1,000 resamples and bias-corrected (BCa) 95% confidence intervals 
(CI) were developed around each beta value (Mooney & Duval, 1993). The equation used to model 
the data in the present study is shown below:
3. Results
3.1. Descriptive results
Descriptive results (Figures 1 and 2) revealed significant range, even among primarily poverty strick-
en countries, in 2014 MCV coverage. Regarding the maps, graduated symbols were used to repre-
sent MCV coverage, where countries with darker colors exhibited lower MCV coverage. The Kingdom 
of Lesotho, which is characterized by high rates of HIV (a virus known to advance the course of 
measles), exhibited the lowest vaccination rate, with 58% of the population having received the first 
dose and 54% of the population having received the second dose. MCV-1 coverage was highest in 
Belarus, Guyana, Kazakhstan, Maldives, Morocco, Saint Lucia, the United Republic of Tanzania, 
Thailand, and Uzbekistan. While each of these countries exhibited at least 99% MCV-1 coverage, 
many demonstrated significant declines in the percentage of the population with MCV-2. For 
log10
(
Y
i
+ 30
)
= 훼 + 훽X
i
+ 휀
i
Figure 1. Percentage of the 
country population with MCV-1 
coverage.
Figure 2. Percentage of the 
country population with MCV-2 
coverage.
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example, only 29% of the population in the United Republic of Tanzania received MCV-2. Overall, 
consistent declines in MCV coverage between first and second dose were observed across many 
countries in the study (Table 1).
Like the disparities in MCV coverage among the countries selected for study, significant variation 
was also observed across economic indicators. Poverty, as measured by the MPI, was highest in 
Niger (MPI = 0.584) and lowest in Belarus (MPI = 0.001). Niger also exhibited the lowest human de-
velopment, as measured by the HDI and the IHDI; however, correspondence between the MPI and 
the HDI was not present for the underserved countries with the least amount of poverty, as relative 
to this study’s population. Specifically, the HDI was highest in Jordan, not Belarus. IHDI was highest 
in Belarus, a result was comparable to the MPI. Means and standard deviations, with BCa 95% CI, for 
the aforementioned variables are shown in Table 1.
3.2. Inferential results
Table 2 displays the results of the inferential analysis. Significant relationships were found between 
MCV-1 and MCV-2 disparities (dependent variable) and the three economic indices selected for com-
parison in the present study. The first regression model, using MPI as the regressor, explained 43.7% 
of the variance in the dependent variable, F (1, 54) = 41.835, p < 0.001. The MPI—which provided the 
most robust explanation of MCV coverage disparities when compared to the other two economic 
indices—exhibited a positive regression weight, indicating that countries with greater multidimen-
sional poverty experienced greater disparities in first to second dose MCV coverage.
Table 1. Descriptive statistics for MCV coverage and economic indicators
a Coverage disparity was calculated by subtracting the percentage of the population in each country that received the 
MCV-2 from the percentage of the population in each country that received the MCV-1.
Variable N M BCa 95% CI (M) SD BCa 95% CI (SD)
Lower Upper Lower Upper
MCV-1 (%) 56 90.553 [88.211 92.756] 9.494 [7.179 11.370]
MCV-2 (%) 56 75.518 [68.500 81.446] 25.716 [20.785 29.622]
Coverage disparitya 56 15.036 [9.369 21.488] 23.363 [18.151 27.271]
MPI 56 0.105 [0.072 0.142] 0.142 [0.110 0.168]
HDI 56 0.651 [0.001 0.015] 0.117 [0.097 0.132]
IHDI 56 0.508 [0.473 0.540] 0.129 [0.114 0.141]
Table 2. OLS regression models for the prediction of first to second dose disparities in MCV 
coverage
a Bootstrap results were based on 1,000 resamples. All regression models were calculated with a Briggsian logarithmic 
transformation to the dependent variable with a constant of 30 applied to each observation.
Model Ba Bias SE (B) BCa 95% CI (B) F df p R2
Lower Upper
1
 Constant 1.507 −0.002 0.027 [1.457 1.556] 41.835 (1, 54) <0.001 0.437
 MPI 0.938 0.008 0.122 [0.715 1.198]
2
 Constant 2.272 −0.010 0.120 [2.048 2.458] 29.627 (1, 54) <0.001 0.354
 HDI −1.023 0.014 0.184 [−1.398 −0.558]
3
 Constant 2.080 −0.003 0.087 [1.908 2.236] 30.468 (1, 54) <0.001 0.361
 IHDI −0.935 0.005 0.167 [−1.266 −0.598]
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The second regression model, using HDI as the regressor, also provided excellent prediction of first 
to second dose disparities in MCV coverage, albeit less than the first regression model. Specifically, 
the HDI model accounted for 35.4% of the variance in the dependent variable, F (1, 54) = 29.627, 
p < 0.001. To the extent that the HDI beta weight was negative, the model indicated that first to 
second dose disparities in MCV coverage were greatest in countries with relatively low human devel-
opment. The third regression model, using IHDI as the regressor, accounted for a greater percentage 
of the variance in the dependent variable than the second model but less than the first model, 
R2 = 0.361, F (1, 54) = 30.468, p < 0.001. The IHDI exhibited a negative beta weight, indicating that 
countries with lower inequality-adjusted human development experienced greater first to second 
dose disparities in MCV coverage.
4. Discussion
Poverty is often associated with lack of adequate resources, and it is likely this inequity partially ex-
plains undervaccination among the countries examined herein. The present research, therefore, fills 
a gap in the literature by exploring how three different poverty indices might each predict the drop-
off in Measles-Containing Vaccine (MCV) coverage from first to second dose. The findings from this 
study confirm that multidimensional poverty has a powerful impact on individuals living in impover-
ished countries receiving the second dose of MCV.
There is a host of extant literature documenting the correlation between underimmunization and 
poverty-related factors in well-developed countries. Indeed, many of the factors that link poverty 
with underimmunization in well-developed countries are present, and often magnified, in impover-
ished countries. Nonetheless, as evidenced by that variance that was unexplained in the three re-
gression models presented in this study, factors beyond mere poverty—at least as measured by 
these three indices—must influence the drop-off from MCV-1 to MCV-2 coverage rates in developing 
countries. One factor perhaps directly related to the disparity in coverage could be vaccine short-
ages. In 2014, 50 of the 194 WHO countries reported experiencing a total of 110 national-level 
shortage of supply of at least one vaccine lasting at least 1 month; in other words, each country 
experienced an average of 2.2 shortages in 2014. Furthermore, MCV alone accounted for 14% of the 
reported shortages (Subaiya et al., 2015). Further complicating supply-side matters, as of 2015, 94% 
of MCV supply was sourced from just one manufacturer, while two other manufacturers supplied the 
remaining 6% (UNICEF Supply Division, 2015).
Additionally, Gavi—the international organization whose goal is to improve access to vaccines in 
the world’s poorest countries—provides many of the countries in this study financing for vaccines 
they might otherwise not be able to afford. As of 2015, Gavi-financed country requirements ac-
counted for approximately 30% of total MCV demand through UNICEF. Though both Gavi-financed 
and non-Gavi financed countries are able to procure MCV at the same prices, more impoverished 
countries are likely more prone to apply for Gavi funding. Gavi relies on the developing countries 
themselves to initiate funding proposals, and the countries then choose what specific support they 
want to apply for and when they wish to receive it (Gavi: The Vaccine Alliance, 2016). This multi-
layered application process itself (including choosing what support they want from the Gavi board 
and compiling the variety of materials required by UNICEF’s Supply Division) requires leaders of 
these countries to have a high level of education about infectious diseases, as well as to understand 
the importance of a particular vaccination schedule; in this case, to receive Gavi funding, country 
leaders would first need to understand why MCV-2 is recommended as a follow-up to MCV-1. It is 
possible that a lack of education about the importance of a second dose of MCV, the cumbersome 
application process itself, or a combination of both factors has contributed to the disparity from 
MCV-1 to MCV-2 administration among the countries examined in this study. For many of these 
countries, it is unknown whether they will apply for funding to cover MCV-2 administration or, should 
they apply, whether the vaccine will even be available (UNICEF Supply Division, 2015).
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4.1. Limitations
Though the findings from this study confirm the impact of poverty on undervaccination, some limita-
tions are inherent. While the MPI explained much of the dropoff from MCV-1 to MCV-2 coverage in 
the countries explored in this study, the unexplained variance suggests there are many other factors 
that likely influence undervaccination rates. Furthermore, this study did not consider specific factors 
related to poverty that might be particularly impactful. While we can deduce that countries with 
greater dimensions of poverty experience greater levels of underimmunization, it would not be ap-
propriate to speculate about the impact of particular dimensions. Every country examined in this 
research has its own specific set of barriers, and as such, researchers should be hesitant to draw 
uniform conclusions based on this study’s findings.
5. Conclusion
5.1. Key findings
This research suggests more multidimensionally-poor countries experience greater MCV dosage 
 disparities; specifically, the Multidimensional Poverty Index (MPI) provided the greatest predictive 
power for the dropoff from first to second dose. Nonetheless, as evidenced by the relatively robust 
predictive power of all three poverty indices—the weakest one accounting for over 35% of the 
 variance in the regression models presented in this study—poverty, no matter how it is measured, is 
a powerful factor in explaining the drop-off from first to second dose MCV administration.
5.2. Implications
This research provides the impetus to explore the various dimensions of poverty and how each 
might impact undervaccination in the world’s poorest countries. One recent study suggested four 
factors significantly associated with MCV-2 uptake in an impoverished country, two of which were 
relevant to the present study: awareness of MCV-2, and time taken to travel to the nearest health 
facility (Makokha, Wanjala, Githuku, & Kutima, 2015). It is possible that a convergence of barriers 
together affects MCV-2 administration, including poverty, application-related difficulties, vaccine 
awareness, and individuals’ proximity to available health centers. These factors nonetheless tend to 
be all exacerbated by poverty, and it is possible that the 56% of unexplained variance in this study is 
related—if indirectly—to factors related to poverty as well.
5.3. Recommendations
Future efforts should be directed toward uncovering and reducing barriers to second dose MCV ad-
ministration in the most impoverished countries. It is crucial to emphasize the continued importance 
of educational efforts that raise awareness of the need for MCV-2. Since the Gavi application process 
requires country leaders to be aware of specific health issues before applying for funding, it would be 
worthwhile to examine whether these leaders fully understand the need for MCV-2 among their 
populations. Additionally, using GIS to map the available health facilities in a country might provide 
a more robust understanding of how the distance between, and availability of, health facilities influ-
ence underimmunization. Nonetheless, all of the dimensions of poverty should be critically exam-
ined in the context of individual countries so public health practitioners can better target 
individualized interventions that address the various factors influencing underimmunization in the 
most impoverished countries.
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